A platform trial for relapsed patients to evaluate ongoing novel therapies in multiple myeloma in combination with standard of care therapies
Latest Information Update: 09 Nov 2023
Price :
$35 *
At a glance
- Drugs Belantamab mafodotin (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ProMMise
- 11 May 2022 Planned End Date changed from 1 Feb 2024 to 1 May 2026.
- 11 May 2022 Recruitment is expected to begin on 11 May' 2022 and recruitment completion is expected on 11 May' 2025 according to ISRCTN: Current Controlled Trials record.
- 15 Mar 2022 Recruitment is expected to begin on 1 Apr' 2022 and recruitment completion is expected on 1 Apr' 2024 according to ISRCTN: Current Controlled Trials record.